T2345
Phase 3Small molecule
T2345 is one of 47 small molecule programs targeting Glaucoma. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
187 competitors in Ocular Hypertension
#DrugCompanyPhaseTrials
1Alphagan
NovartisPhase 3
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Azopt
NovartisPhase 3
Ocupress
AbbViePhase 3
Krytantek
AbbViePhase 3
LUMIGAN
AbbViePhase 3
Bimatoprost/timolol
AbbViePhase 3
Preservative-Free Tafluprost
Merck & Co.Phase 3
T2345
LLaboratoires Thea
Phase 3
Reference - LUMIGAN
AAmneal Pharmaceuticals, LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for T2345. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLaboratoires Thea